BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37000008)

  • 41. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
    Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
    Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.
    Yang L; Liu H; Xu XH; Wang XF; Huang HM; Shi WY; Jiang SH
    Med Oncol; 2013 Dec; 30(4):720. PubMed ID: 24062259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
    Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
    Qiu C; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1420-1425. PubMed ID: 29070118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of patients treated with SVILE
    Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
    Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
    [No Abstract]   [Full Text] [Related]  

  • 46. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.
    Kim SM; Park S; Oh DR; Ahn YC; Ko YH; Kim SJ; Kim WS
    Ann Hematol; 2016 Mar; 95(4):581-91. PubMed ID: 26729202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
    Yuan FF; Yin QS; Fu YW; Wang Q; Chen L; Mi RH; Li YF; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):569-572. PubMed ID: 30122016
    [No Abstract]   [Full Text] [Related]  

  • 49. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
    Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
    Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type.
    Lin N; Song Y; Zheng W; Tu M; Xie Y; Wang X; Ping L; Ying Z; Zhang C; Deng L; Liu W; Zhu J
    J Hematol Oncol; 2013 Jul; 6():44. PubMed ID: 23816178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
    Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
    Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
    Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
    [No Abstract]   [Full Text] [Related]  

  • 57. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
    Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
    Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
    Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
    Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.